Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 4/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28655414 | 0.87 | HSD17B1 (0.78) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL1746656 | 0.84 | HSD17B1 (0.69) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL3987535 | 0.82 | HSD17B1 (0.62) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL24570624 | 0.81 | HSD17B1 (0.53) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL30584396 | 0.81 | HSD17B1 (0.53) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL6192593 | 0.79 | PARP10 (0.64) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL1745161 | 0.78 | HSD17B1 (0.71) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL1030949 | 0.76 | HSD17B1 (1.00) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL28655417 | 0.76 | HSD17B1 (0.65) | HSD17B1CYP1A2CYP11B1CYP11B2PGR | |
| SCHEMBL30456099 | 0.76 | HSD17B1 (0.65) | HSD17B1CYP1A2CYP11B1CYP11B2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485655-B2 | 2-Aminothiazole allosteric enhancers of A1 adenosine receptors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1583530-A4 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS | UNIV VIRGINIA (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1583530-A1 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050027125-A1 | 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-03 | — | — | US | disclosed |
| WO-2003061655-A1 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1 ADENOSINE RECEPTORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027125-A1 | 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors | ADORA1, ADORA2A, ADORA2B | HSD17B1 4023/4885CYP1A2 2684/4885CYP11B1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.